Reaction Details |
| Report a problem with these data |
Target | MAP kinase-activated protein kinase 2 |
---|
Ligand | BDBM50344718 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_749048 (CHEMBL1780645) |
---|
EC50 | 8.3±n/a nM |
---|
Citation | Kaptein, A; Oubrie, A; de Zwart, E; Hoogenboom, N; de Wit, J; van de Kar, B; van Hoek, M; Vogel, G; de Kimpe, V; Schultz-Fademrecht, C; Borsboom, J; van Zeeland, M; Versteegh, J; Kazemier, B; de Roos, J; Wijnands, F; Dulos, J; Jaeger, M; Leandro-Garcia, P; Barf, T Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors. Bioorg Med Chem Lett21:3823-7 (2011) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
MAP kinase-activated protein kinase 2 |
---|
Name: | MAP kinase-activated protein kinase 2 |
Synonyms: | MAP kinase-activated protein kinase 2 (MAPKAPK2) | MAP kinase-activated protein kinase 2 (MK2) | MAP kinase-activated protein kinase 2 (p38/MK2) | MAPK-Activated Protein Kinase 2 (MK2) | MAPK-activated protein kinase 2 | MAPK2_HUMAN | MAPKAP kinase 2 | MAPKAPK-2 | MAPKAPK2 | MK2 |
Type: | Serine/threonine-protein kinase |
Mol. Mass.: | 45579.87 |
Organism: | Homo sapiens (Human) |
Description: | P49137 |
Residue: | 400 |
Sequence: | MLSNSQGQSPPVPFPAPAPPPQPPTPALPHPPAQPPPPPPQQFPQFHVKSGLQIKKNAII
DDYKVTSQVLGLGINGKVLQIFNKRTQEKFALKMLQDCPKARREVELHWRASQCPHIVRI
VDVYENLYAGRKCLLIVMECLDGGELFSRIQDRGDQAFTEREASEIMKSIGEAIQYLHSI
NIAHRDVKPENLLYTSKRPNAILKLTDFGFAKETTSHNSLTTPCYTPYYVAPEVLGPEKY
DKSCDMWSLGVIMYILLCGYPPFYSNHGLAISPGMKTRIRMGQYEFPNPEWSEVSEEVKM
LIRNLLKTEPTQRMTITEFMNHPWIMQSTKVPQTPLHTSRVLKEDKERWEDVKEEMTSAL
ATMRVDYEQIKIKKIEDASNPLLLKRRKKARALEAAALAH
|
|
|
BDBM50344718 |
---|
n/a |
---|
Name | BDBM50344718 |
Synonyms: | 2'-(2-(3-fluorophenyl)pyrimidin-4-yl)-5',6'-dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]-4'(1'H)-one | CHEMBL1779350 |
Type | Small organic molecule |
Emp. Form. | C21H20FN5O |
Mol. Mass. | 377.4148 |
SMILES | Fc1cccc(c1)-c1nccc(n1)-c1cc2c([nH]1)C1(CCNCC1)CNC2=O |
Structure |
|